138 related articles for article (PubMed ID: 37285318)
1. Effect of stage shift and immunotherapy treatment on lung cancer survival outcomes.
Patel P; Flores R; Alpert N; Pyenson B; Taioli E
Eur J Cardiothorac Surg; 2023 Aug; 64(2):. PubMed ID: 37285318
[TBL] [Abstract][Full Text] [Related]
2. Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.
Potter AL; Rosenstein AL; Kiang MV; Shah SA; Gaissert HA; Chang DC; Fintelmann FJ; Yang CJ
BMJ; 2022 Mar; 376():e069008. PubMed ID: 35354556
[TBL] [Abstract][Full Text] [Related]
3. Unequal racial distribution of immunotherapy for late-stage non-small cell lung cancer.
Chang A; Flores RM; Taioli E
J Natl Cancer Inst; 2023 Oct; 115(10):1224-1226. PubMed ID: 37421405
[TBL] [Abstract][Full Text] [Related]
4. Association of Stage Shift and Population Mortality Among Patients With Non-Small Cell Lung Cancer.
Flores R; Patel P; Alpert N; Pyenson B; Taioli E
JAMA Netw Open; 2021 Dec; 4(12):e2137508. PubMed ID: 34919136
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer.
Pichert MD; Canavan ME; Maduka RC; Li AX; Ermer T; Zhan PL; Kaminski M; Udelsman BV; Blasberg JD; Park HS; Goldberg SB; Boffa DJ
JAMA Netw Open; 2022 Aug; 5(8):e2224478. PubMed ID: 35925606
[TBL] [Abstract][Full Text] [Related]
7. Residence in Rural Areas of the United States and Lung Cancer Mortality. Disease Incidence, Treatment Disparities, and Stage-Specific Survival.
Atkins GT; Kim T; Munson J
Ann Am Thorac Soc; 2017 Mar; 14(3):403-411. PubMed ID: 28118039
[TBL] [Abstract][Full Text] [Related]
8. Persistence of racial disparities in early-stage lung cancer treatment.
Wolf A; Alpert N; Tran BV; Liu B; Flores R; Taioli E
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1670-1679.e4. PubMed ID: 30685165
[TBL] [Abstract][Full Text] [Related]
9. Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.
Iezzoni LI; Ngo LH; Li D; Roetzheim RG; Drews RE; McCarthy EP
Arch Phys Med Rehabil; 2008 Apr; 89(4):595-601. PubMed ID: 18373987
[TBL] [Abstract][Full Text] [Related]
10. Use and Outcomes of Low-Dose CT Scan Lung Cancer Screening in the Medicare Population.
Pinsky PF; Miller E
Chest; 2022 Sep; 162(3):721-729. PubMed ID: 35364090
[TBL] [Abstract][Full Text] [Related]
11. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
13. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
[No Abstract] [Full Text] [Related]
14. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly.
Shirvani SM; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Smith BD
JAMA Surg; 2014 Dec; 149(12):1244-53. PubMed ID: 25321323
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
Oncologist; 2013; 18(5):600-10. PubMed ID: 23635558
[TBL] [Abstract][Full Text] [Related]
17. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
18. Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.
Youn B; Wilson IB; Mor V; Trikalinos NA; Dahabreh IJ
Health Serv Res; 2021 Jun; 56(3):486-496. PubMed ID: 33682120
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center.
Thibodeau S; Meem M; Hopman W; Sandhu S; Zalay O; Fung AS; Kartolo A; Digby GC; Al-Ghamdi S; Robinson A; Ashworth A; Owen T; Mahmud A; Tam K; Olding T; de Moraes FY
Cancer Treat Res Commun; 2023; 36():100747. PubMed ID: 37531737
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Gray SW; Chen AB; Weeks JC; Schrag D
JAMA; 2012 Apr; 307(15):1593-601. PubMed ID: 22511687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
